Published Reported
Marius Pharmaceuticals Applauds FDA’s Proposed Testosterone Labeling Updates as a Turning Point for Men’s Health
A cardiovascular outcomes trial of more than 5,200 men found no meaningful increase in major adverse cardiovascular events, and testosterone deficiency is a widespread, undertreated condition.